Expression of TN5 transposase for next generation sequencing protocol of HIV ad selected oncoviruses

Abstract

Objective: The development of HIV drug resistance is a significant challenge in maintaining suppressed viral load in the management of patients. Next generation sequencing (NGS) is a more sensitive approach to determine the burden of HIV drug resistance. We aimed to describe the uptake of NGS in HIV drug resistance studies in Africa. Methodology: Electronic search was done for studies published between 2005 and 2019, from three databases: Pubmed, Web of Science and Google scholar. The search approach was carried out according to PRISMA guidelines. Studies included in the analysis were those that reported the use of NGS on HIV drug resistance using samples from Africa or in which the studies were done in Africa. Only articles published in English were included in the analysis. Results: Four thousand one hundred and eighty articles were identified according to the search criteria. Out of these, 238 studies met the inclusion criteria and were included in the analysis. Thirty studies (12.6%) used NGS, 194 (81.5%) used Sanger sequencing, and 14 (5.9%) used both techniques. Evidence of in-country application of NGS was observed in six studies (13.6%), all from South Africa. In other studies, NGS was either done outside of Africa using samples obtained from Africa or the country in which NGS was done was not indicated. From 2005 to 2012, only one study was reported on HIV drug resistance using NGS; however, 44 studies were published by 2019. Out of the 54 African countries, investigators from 13 countries (24.1%) published data on HIV drug resistance using NGS, as at end of 2019. Conclusion: There is an uptake in the application of NGS in HIV drug resistance studies in Africa, albeit in a slower pace, with investigators from about a quarter of African countries applying the technology for this purpose.